Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use

Table 5 Risk factors related to anti-tumor necrosis factor alpha use

		Total	Anti-TNFα No	Anti-TNFα Yes	P value
Sex (%)					0.731
	Male	318 (57.7)	288 (57.5)	30 (60.0)
	Female	233 (42.3)	213 (42.5)	20 (40.0)
Age (%)		40.56 ± 16.11	41.10 ± 16.76	38.36 ± 16.05	0.268
					0.913
	< 60 yr	278 (50.5)	428 (85.4)	43 (86.0)
	≥ 60 yr	273 (49.5)	73 (14.6)	7 (14.0)
Smoking (%)					0.422
	No	366 (82.6)	329 (83.1)	37 (78.7)
	Yes	77 (17.4)	67 (16.9)	10 (21.3)
BMI (%)					0.667
	< 25 kg/m2	295 (83.3)	260 (83.6)	35 (81.4)
	≥ 25 kg/m2	59 (16.7)	51 (16.4)	8 (18.6)
Mayo score at diagnosis (%)					0.001
	Mild	179 (44.9)	170 (47.6)	9 (21.4)
	Moderate + severe	220 (55.1)	187 (52.4)	33 (78.6)
Disease extent at diagnosis (%)					0.000
	Proctitis + left side	413 (75.5)	394 (79.3)	19 (38.0)
	Extensive	134 (24.5)	103 (20.7)	31 (62.0)
CRP level at diagnosis (%)					0.536
	< 5 mg/dL	265 (79.3)	17 (73.9)	282 (79.0)
	≥ 5 mg/dL	69 (20.7)	6 (26.1)	75 (21.0)
Steroid use after diagnosis					0.269
	< 2 mo		116 (57.1)	31 (66.0)
	≥ 2 mo		87 (42.9)	16 (34.0)
AZA/6MP use after diagnosis					0.741
	< 2 mo	47 (29.2)	37 (29.8)	10 (27.0)
	≥ 2 mo	114 (70.8)	87 (70.2)	27 (73.0)
Diagnostic delay (%)					0.019
	< 24 mo	509 (92.4)	467 (93.2)	42 (84.0)
	≥ 24 mo	42 (7.6)	34 (6.8)	8 (16.0)

Anti-TNFα: Anti-tumor necrosis factor alpha; BMI: Body mass index; AZA/6MP: Azathioprine or 6-mercaptopurine.